Skip to Content

Targiniq ER Approval History

FDA Approved: Yes (Discontinued) (First approved July 23, 2014)
Brand name: Targiniq ER
Generic name: naloxone and oxycodone
Dosage form: Extended-Release Tablets
Company: Purdue Pharma LP
Treatment for: Pain

Marketing Status: Discontinued

Targiniq ER (naloxone and oxycodone) is an opioid antagonist and opioid analgesic combination in a long-acting abuse-deterrent formulation for the management of chronic severe pain.

Development History and FDA Approval Process for Targiniq ER

DateArticle
Jul 23, 2014Approval FDA Approves Targiniq ER Extended-Release Oxycodone with Abuse-Deterrent Properties
Nov 26, 2013FDA Accepts for Review Purdue Pharma’s New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCL Controlled-Release) Tablets CII

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide